News
Covid, Moderna and FDA
Digest more
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to ...
Arboviruses are spreading beyond tropical and subtropical regions due to climate change, population growth, and increased ...
Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...
On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback